Based on amino acid sequence similarity, the ZIP family was divided into four subfamilies: ZIPI, ZIPII, GufA, and LZT. SCL39A13 belongs to the LZT family, the members of which share the Pro-Ala-Leu (PAL) and His-Glu-X-X-His (HEXXH) motifs. The conserved PAL motif is in the N-terminal region and may be involved in protein processing. The HEXXH motif is located within the TM5 region. However, SLC39A13 also possesses some domains that are not found in other LZT family members. SLC39A13 is mainly expressed and functions in mesenchyme-originating cells. Moreover, it is localized to the Golgi apparatus and intracellular vesicles. ZIP13 has a putative 8 membrane-spanning segments and the N terminus and C terminus of this protein facing the luminal side.
Basic Information of SLC39A13 | |
Protein Name | Zinc transporter ZIP13 |
Gene Name | SLC39A13 |
Aliases | Solute carrier family 39 member 13, Zrt- and Irt-like protein 13, ZIP13 |
Organism | Homo sapiens (Human) |
UniProt ID | Q96H72 |
Transmembrane Times | 8 |
Length (aa) | 371 |
Sequence | MPGCPCPGCGMAGPRLLFLTALALELLERAGGSQPALRSRGTATACRLDNKESESWGALLSGERLDTWICSLLGSLMVGLSGVFPLLVIPLEMGTMLRSEAGAWRLKQLLSFALGGLLGNVFLHLLPEAWAYTCSASPGGEGQSLQQQQQLGLWVIAGILTFLALEKMFLDSKEEGTSQAPNKDPTAAAAALNGGHCLAQPAAEPGLGAVVRSIKVSGYLNLLANTIDNFTHGLAVAASFLVSKKIGLLTTMAILLHEIPHEVGDFAILLRAGFDRWSAAKLQLSTALGGLLGAGFAICTQSPKGVVGCSPAAEETAAWVLPFTSGGFLYIALVNVLPDLLEEEDPWRSLQQLLLLCAGIVVMVLFSLFVD |
As a member of the SLC39 family, SLC39A13 mediates Zn2+ influx. The zinc transporter protein SLC39A13 plays critical roles in bone, tooth, and connective tissue development. Dysfunction of the SLC39A13 transporter can lead to a genetic disorder of connective tissues, bones, and teeth, which is named the spondylocheiro dysplastic form of Ehlers-Danlos syndrome (SCD-EDS). Patients with this genetic disorder show short stature, skeletal dysplasia of the spine, and clinical abnormalities of the hands and teeth, in addition to the common features of EDS such as skin and joint looseness.
Fig.1 The predicted topology model of ZIP13. (Kambe,2014)
This study investigated the molecular pathogenic mechanism of SCD-EDS caused by two different mutant ZIP13 proteins that were found in human patients, one is the ZIP13(G64D) and the other is ZIP13(ΔFLA). The findings uncovered the pathogenic mechanisms elicited by these two mutant proteins.
This study identified the ZIP13 proteins as the iron transporter responsible for iron delivery to the secretory compartments.
This study conducted a biochemical characterization of the human ZIP13 protein, which provided important information for further investigations of its structural characteristics and function.
This study investigated the underlying mechanisms of the genetic mutations in ZIP13 leading to reduced adipose tissue mass in humans. The results showed that the ZIP13 suppressed beige adipocyte biogenesis and energy expenditure by regulating C/EBP-β expression. This might contribute significantly to the development of new therapies for obesity and metabolic syndrome.
This study investigated the characteristics of the dermis of the Zip13-knockout (KO) mouse, an animal model for SCD-EDS. The results suggested that skin fragility due to defective ZIP13 protein may be owing to impaired extracellular matrix synthesis accompanied by abnormal peripheral transforming growth factor-β homeostasis.
Creative Biolabs introduces our powerful Magic™ Membrane Protein Production Platform to provide custom-specific services for reconstitution of membrane proteins into different systems, including detergents micelles, liposomes, nanodiscs, and polymers. Strategies are flexible and can be tailored to maximally preserve the structural and functional integrity of your proteins. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC39A13 antibody development services.
Contact us to learn more about our membrane protein preparation services.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.